Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-01-13
DOI
10.1093/jac/dkab015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
- (2020) Ryan K. Shields ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
- (2020) Alyssa R. Golden et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
- (2020) Michael Dagher et al. Open Forum Infectious Diseases
- Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?
- (2020) Patricia J. Simner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3
- (2020) Saquib Malik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution
- (2020) C. Paul Morris et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant Enterobacter hormaechei
- (2020) Soline Siméon et al. Microorganisms
- Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
- (2019) Takayuki Katsube et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17
- (2019) Sibylle H Lob et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report
- (2019) Enrico Maria Trecarichi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug resistant Pseudomonas aeruginosa : A case report
- (2019) Ryan W. Stevens et al. PHARMACOTHERAPY
- Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
- (2019) Cornelius J Clancy et al. Open Forum Infectious Diseases
- Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model
- (2019) James M. Kidd et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
- (2019) Malcom G P Page CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
- (2019) Yohei Doi CLINICAL INFECTIOUS DISEASES
- Resistance to Ceftazidime-Avibactam and Underlying Mechanisms
- (2019) Yuhang Wang et al. Journal of Global Antimicrobial Resistance
- Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
- (2019) Sarah C J Jorgensen et al. Open Forum Infectious Diseases
- Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
- (2018) Yutaka Saisho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
- (2018) Takayuki Katsube et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
- (2018) Toshiaki Aoki et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
- (2018) Islam M. Ghazi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cross-reactivity in β-Lactam Allergy
- (2018) Robert J. Zagursky et al. Journal of Allergy and Clinical Immunology-In Practice
- Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study
- (2018) Elizabeth Temkin et al. Lancet Global Health
- Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
- (2018) Sean M Stainton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa
- (2018) Jonathan D Edgeworth et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
- (2017) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
- (2017) Shuhei Matsumoto et al. Open Forum Infectious Diseases
- Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
- (2016) Takayuki Katsube et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanisms of antimicrobial resistance in Gram-negative bacilli
- (2015) Étienne Ruppé et al. Annals of Intensive Care
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started